We have partnered with Neurosoft Bioelectronics, a neural data company developing ultra-soft, flexible neural probes to achieve full cortical coverage powering foundation AI models of the brain, to grant Neurosoft access to Science’s world-class clinical-grade neural engineering capabilities known as the Science Ecosystem.
Science Ecosystem partners enter into multiyear agreements to develop brain-computer interface (BCI) products on Science’s end-to-end neural engineering technology stack, and either bring a novel probe of their own or work with Science Foundry to develop one. This gives partners access to a complete suite of electronics and application development tooling for a fraction of the cost and time of developing it themselves, enabling them to focus on their core innovations and reach patients faster.
Neurosoft is developing minimally invasive, fully implantable BCI systems that leverage state-of-the-art soft materials engineering and artificial intelligence to restore function in people with tinnitus, epilepsy, and other disorders. While its groundbreaking technology has already been used in a dozen human patients, the company is now leveraging the Science Ecosystem to eliminate the cost and complexity of custom hardware development for translation into marketable, scalable products.
It can cost upwards of $75–100 million to build a full-stack clinical-grade BCI platform. The Ecosystem partnership gives innovators access to state-of-the-art BCI capabilities that enables first-in-human trials for as little as $5 million and in a fraction of the time.
Science uses our ecosystem technologies for our own flagship products, including our biohybrid neural interfaces and the forthcoming next generation of our PRIMA retinal prosthesis. Beyond Science’s core interests, there is a long list of important unmet medical needs which can be addressed by leveraging the same underlying technologies, and we have created the Science Ecosystem program to enable innovative partners to make an impact with substantially improved capital efficiency.
“Neural engineering advances happen at the intersection of new probe technologies matched to applications and the electronics and software required to use them,” shared Max Hodak, CEO and cofounder of Science. “By providing robust, modular building blocks designed to meet the requirements of the most rigorous modern BCI applications, we are enabling innovation leaders across the BCI industry to develop targeted therapeutic solutions without rebuilding fundamental infrastructure, ultimately bringing transformative therapies to patients faster.”
Nicolas Vachicouras, PhD, CEO and cofounder of Neurosoft, said: “This partnership with Science is a strategic move that aggressively accelerates clinical adoption, bringing potentially life-changing therapies to patients faster than ever seen before in the industry, while rapidly scaling the high-fidelity neural data collection essential for powering Neurosoft’s foundation AI model.”
“Neurosoft is the ideal partner to debut this model,” said Darius Shahida, Chief Strategy Officer at Science. “This partnership reflects Science’s broader vision to foster a community of BCI innovators working toward life-changing therapies for neurological injury and disease, and to advance the field by reducing development cost and complexity. Our multiyear, multimillion dollar agreement is a significant milestone. I fully expect it will be the first of many.”
